Hospitalist Doctors in Saint Joseph, MI Accepting Medicare

6 Hospitalist doctors found. Showing 1 - 6

Manuel Enrrique Cantor Varela, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1234 Napier Ave, Saint Joseph, MI 49085 Phone: 269-982-4862    Fax: 269-985-4523

Nerihan Hadji, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1234 Napier Ave, Saint Joseph, MI 49085 Phone: 269-985-4632

Patrick J. Mcnellis, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 1234 Napier Ave, Saint Joseph, MI 49085 Phone: 269-985-4632    Fax: 269-985-4623

Stanley A James, M.D. Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 3911 Stonegate Park, Saint Joseph, MI 49085 Phone: 269-408-1777    Fax: 269-408-1755

Daniel Davis Bosis Jr., M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1234 Napier Ave, Saint Joseph, MI 49085 Phone: 269-985-4632

Neethi Sural, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3950 Hollywood Rd, Suite 270, Saint Joseph, MI 49085 Phone: 269-983-0500

News Archive

Alizé Pharma completes two Phase I clinical trials of AZP-531 in healthy volunteers, obese subjects

Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announces today the completion of two Phase I clinical trials with its unacylated ghrelin analog AZP-531 in 76 healthy volunteers and overweight or obese subjects.

New 'people-centered investment approach' could lead to end of global AIDS pandemic

Writing in Huffington Post's "The Big Push" blog, Lucy Chesire, executive director and secretary to the board of the TB ACTION Group, notes "countries from north and south, U.N. organizations, private sector companies and non-governmental organizations (NGOs) are meeting in Geneva [this week] at the Board meeting of the Global Fund to Fight AIDS, Tuberculosis and Malaria to discuss how best to invest available resources against the three killer diseases."

Astellas suspends patient enrollment from ACT 5 study of KYNAPID

Cardiome Pharma Corp. today announced that its co-development partner, Astellas Pharma US., Inc., has suspended patient enrollment in the ACT 5 study of KYNAPIDTM (vernakalant hydrochloride) Injection following a single unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received KYNAPID.

Cesarean section carries independent risk in multiple births, shows study

The authors assert that cesarean section carries an independent risk in multiple births. They defend the benefits of vaginal delivery and promote the use of cesarean section as an option

Read more Medical News

› Verified 2 days ago